Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivekimab sunirine - ImmunoGen

Next Previous
Drug Profile

Pivekimab sunirine - ImmunoGen

Alternative Names: IMGN-632; PVEK - ImmunoGen

Latest Information Update: 14 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer Fred Hutchinson Cancer Research Center; ImmunoGen; Jazz Pharmaceuticals plc
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Indoles; Monoclonal antibodies; Pyrrolidines
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Blastic plasmacytoid dendritic cell neoplasm; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
  • Phase I Myelodysplastic syndromes
  • No development reported Haematological malignancies

Most Recent Events

  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 14 Dec 2023 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy, Late-stage disease) in USA (IV) (NCT06034470)
  • 14 Dec 2023 Phase-I clinical trials in Myelodysplastic syndromes (First-line therapy, Combination therapy, Late-stage disease) in USA (IV) (NCT06034470)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top